Healthy
Conditions
Keywords
Phase 1, healthy volunteers, cross-over study, ceftaroline fosamil, various infusion volumes, local tolerability, Cmax, tmax, AUC
Brief summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of Ceftaroline 600 mg when administered by varying infusion volumes.
Detailed description
A Phase I, Single-center, 2-part, Randomized, 2-way Crossover Study to Assess the Local Tolerability and Safety (Multiple-dose) and to Assess the Pharmacokinetics, Safety, and Tolerability (Single-dose) of Ceftaroline in Healthy Subjects when Ceftaroline Fosamil is Diluted in Various Infusion Volume
Interventions
DRUG600 mg ceftaroline fosamil in 50 ml infusion volume
IV infusion
DRUGPlacebo in 50 ml infusion volume
IV infusion
DRUG600 ceftaroline fosamil in 250 ml infusion volume
IV infusion
DRUGPlacebo in 250 ml infusion volume
IV infusion
DRUG600 mg ceftaroline in 100 ml infusion volume
IV infusion
DRUGPlacebo in 100 ml infusion volume
IV infusion
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Provision of informed consent prior to any study specific requirements * Women of childbearing potential must have a negative pregnancy test, be non-lactating, and be using a highly effective form of birth control for 3 months prior to enrollment, during the study, and for 3 months after completion of all study-related proceed * Male volunteers must be willing to use barrier contraception from the first day of dosing until 3 months after the last dose of IP. * Have a body mass index (BMI) between 18 and 30 kg/m2, and weigh at least 50 kg * Healthy male and/or female volunteers between the ages of 18 to 75 years inclusive, with veins on the back of both hands and both forearms suitable for cannulation or repeated venipuncture.
Exclusion criteria
* Use of any other investigational compound or participation in another clinical trial within 1 month prior to first administration of IP in this study * History of any clinically significant disease or disorder (e.g., neurological, haematological, psychiatric, gastrointestinal, hepatic, renal disease) * Positive serology result on screening for serum hepatitis B surface antigen, hepatitis C antibody (HCV), or human immunodeficiency virus (HIV) * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs * Any clinically significant abnormalities in the physical examination, lab, 12-lead ECG or vital signs as judged by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 24-hour pharmacokinetic profile in terms of (see description) for ceftaroline following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes | Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose | Maximum plasma concentration (Cmax) Time to maximum concentration (tmax) Area under the concentration-time curve from zero to infinity (AUC) Area under the plasma concentration-time curve from zero to time of the last quantifiable concentrations \[AUC(0-t)\] Area under the plasma concentration-time curve from zero to 12 hours after the start of the infusion \[AUC(0-12)\] |
| 24-hour pharmacokinetic profile in terms of (see description)for ceftaroline following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes | Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose | Apparent terminal elimination rate constant (Lz) Half-life associated with the terminal slope (t½Lz),mean residence time (MRT) Total body clearance of drug from plasma (CL) Volume of distribution based on the terminal phase(Vz) Volume of distribution at steady state (Vss) Cmax ratios of ceftaroline/ceftaroline fosamil and ceftaroline M-1/ceftaroline (RM/D,Cmax) AUC ratios of ceftaroline/ceftaroline fosamil and ceftaroline M-1/ceftaroline (RM/D,AUC) |
| Local tolerability in terms of adverse events including local infusion site tolerability for ceftaroline following ceftaroline 600 mg diluted in various infusion volumes every 12 hours for 72 hours | From baseline to 14 days after first dose | Baseline is defined as - Screening up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety profile in terms of vital signs, ECG, laboratory variables, physical examination for ceftaroline following ceftaroline 600 mg diluted in various infusion volumes every 12 hours for 72 hours | From baseline to 14 days after first dose | Baseline is defnied as - Screening up |
| 24-hour pharmacokinetic profile in terms of ( see description) for ceftaroline fosamil and ceftaroline M-1following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes | Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose | Maximum plasma concentration (Cmax) Time to maximum concentration (tmax) Area under the concentration-time curve from zero to infinity (AUC) Area under the plasma concentration-time curve from zero to time of the last quantifiable concentrations \[AUC(0-t)\] Area under the plasma concentration-time curve from zero to 12 hours after the start of the infusion \[AUC(0-12)\] |
| Safety and tolerability profile in terms of adverse events, vital signs, ECG, laboratory variables, physical exam of ceftaroline following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes | From baseline to 14 days after first dose) | Baseline is defined as- Screening up. |
Countries
United Kingdom
Outcome results
None listed